LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Cerrado

SectorSanidad

16.65 2.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

16.14

Máximo

16.88

Métricas clave
By Trading Economics
Ingresos	614M 331M
Ventas	288M 731M
P/B Media del Sector	48.586 49.888
BPA	3.16
Margen de beneficios	45.287
Empleados	835
EBITDA	628M 375M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+36.45% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-531M 1.8B
Apertura anterior	14.06
Cierre anterior	16.65

Noticias sobre sentimiento de mercado

By Acuity

50%

155 / 344 Clasificación en Healthcare

Sarepta Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 15:04 UTC

Principales Movimientos del Mercado

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21 jul 2025, 11:31 UTC

Principales Movimientos del Mercado

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6 may 2026, 22:50 UTC

Ganancias

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26 ene 2026, 09:55 UTC

Acciones populares

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4 nov 2025, 14:39 UTC

Ganancias

Acciones populares

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4 nov 2025, 12:45 UTC

Ganancias

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11 ago 2025, 11:48 UTC

Ganancias

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11 ago 2025, 11:11 UTC

Ganancias

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29 jul 2025, 21:11 UTC

Ganancias

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29 jul 2025, 12:14 UTC

Ganancias

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29 jul 2025, 11:46 UTC

Ganancias

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21 jul 2025, 12:53 UTC

Ganancias

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 jul 2025, 11:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 jul 2025, 10:25 UTC

Ganancias

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 jul 2025, 09:50 UTC

Ganancias

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 jul 2025, 09:12 UTC

Ganancias

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 jul 2025, 16:44 UTC

Ganancias

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 jul 2025, 13:48 UTC

Ganancias

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 jul 2025, 10:57 UTC

Ganancias

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 jul 2025, 09:08 UTC

Acciones populares

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 jun 2025, 09:10 UTC

Acciones populares

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 jun 2025, 08:59 UTC

Acciones populares

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 jun 2025, 08:55 UTC

Acciones populares

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Comparación entre iguales

Cambio de precio

Sarepta Therapeutics Inc previsión

Precio Objetivo

By TipRanks

36.45% repunte

Estimación a 12 Meses

Media 22.16 USD 36.45%

Máximo 38 USD

Mínimo 5 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sarepta Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

20 ratings

Comprar

Mantener

Vender

De acuerdo con 20 analistas que ofrecen calificaciones bursátiles a para Sarepta Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

155 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.